Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2007-09-11

Clinical Trial Update: Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update assessing the glucose-lowering effect, safety and tolerability of CS-917 in adults with type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CS-917

Snippet

Sponsor: Daiichi Sankyo | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED